BACKGROUND: Programmed cell death protein 1 (PD-1) inhibitors are the first-line treatment for advanced non-small-cell lung cancer (NSCLC) patients. However, their efficacy in metastatic NSCLC patients remains controversial. AIM OF THE STUDY: The aim of our study was to evaluate the prognosis of advanced metastatic NSCLC patients treated with PD-1 inhibitors, and discuss the predictive effect of metastatic site on the long-term outcome. METHODS: The Embase, Ovid Medline, Cochrane Central Register of Controlled Trials, and PubMed databases were systematically screened up to February 10, 2020. Twenty-five eligible studies, involving 8,067 patients that assessed the impact of metastatic sites on survival outcome were incorporated in our study. Overall survival (OS) and progression-free survival (PFS) were described as hazard ratio (HR) with 95% confidence interval (CI). RESULTS: Among the advanced NSCLC patients, the median proportion of brain, liver, bone, and adrenal gland metastases were 21%, 17%, 35%, and 21%, respectively. Patients with metastases to the brain, liver, and bone had worse OS compared to patients without these metastases when treated with PD-1 inhibitors. Similarly, patients with metastasis to the brain and liver were more likely to progress when treated with PD-1 inhibitors. Besides, patients with multiple metastatic sites had worse PFS compared to patients with one metastatic site, while no significant difference was found in terms of OS. CONCLUSIONS: Based on the findings of our systematic review and meta-analysis, metastatic sites were independent predictors of the survival outcome for advanced NSCLC patients treated with PD-1 inhibitors.
BACKGROUND:Programmed cell death protein 1 (PD-1) inhibitors are the first-line treatment for advanced non-small-cell lung cancer (NSCLC) patients. However, their efficacy in metastatic NSCLCpatients remains controversial. AIM OF THE STUDY: The aim of our study was to evaluate the prognosis of advanced metastatic NSCLCpatients treated with PD-1 inhibitors, and discuss the predictive effect of metastatic site on the long-term outcome. METHODS: The Embase, Ovid Medline, Cochrane Central Register of Controlled Trials, and PubMed databases were systematically screened up to February 10, 2020. Twenty-five eligible studies, involving 8,067 patients that assessed the impact of metastatic sites on survival outcome were incorporated in our study. Overall survival (OS) and progression-free survival (PFS) were described as hazard ratio (HR) with 95% confidence interval (CI). RESULTS: Among the advanced NSCLCpatients, the median proportion of brain, liver, bone, and adrenal gland metastases were 21%, 17%, 35%, and 21%, respectively. Patients with metastases to the brain, liver, and bone had worse OS compared to patients without these metastases when treated with PD-1 inhibitors. Similarly, patients with metastasis to the brain and liver were more likely to progress when treated with PD-1 inhibitors. Besides, patients with multiple metastatic sites had worse PFS compared to patients with one metastatic site, while no significant difference was found in terms of OS. CONCLUSIONS: Based on the findings of our systematic review and meta-analysis, metastatic sites were independent predictors of the survival outcome for advanced NSCLCpatients treated with PD-1 inhibitors.
Entities:
Keywords:
Non-small cell lung cancer; PD-1; metastatic site
Authors: Kurt G Tournoy; Michiel Thomeer; Paul Germonpré; Sofie Derijcke; Rebecca De Pauw; Daniëlla Galdermans; Karl Govaert; Elke Govaerts; Rob Schildermans; Isabelle Declercq; Nele De Brucker; Karin Pat; Rika Van Herreweghe; Luc Van Zandweghe; Luc Vanmaele; Valerie Van Damme; Heidi Marien; Sofie De Craene; Isabelle Fabry; Patrick Alexander; Piet Vercauter; Ingel Demedts Journal: Lung Cancer Date: 2017-11-16 Impact factor: 5.705
Authors: Shirish M Gadgeel; Rimas V Lukas; Jerome Goldschmidt; Paul Conkling; Keunchil Park; Diego Cortinovis; Filippo de Marinis; Achim Rittmeyer; Jyoti D Patel; Joachim von Pawel; Carol O'Hear; Catherine Lai; Sylvia Hu; Marcus Ballinger; Alan Sandler; Mayank Gandhi; Lou Fehrenbacher Journal: Lung Cancer Date: 2018-12-19 Impact factor: 5.705
Authors: Jeffrey Weber; Mario Mandala; Michele Del Vecchio; Helen J Gogas; Ana M Arance; C Lance Cowey; Stéphane Dalle; Michael Schenker; Vanna Chiarion-Sileni; Ivan Marquez-Rodas; Jean-Jacques Grob; Marcus O Butler; Mark R Middleton; Michele Maio; Victoria Atkinson; Paola Queirolo; Rene Gonzalez; Ragini R Kudchadkar; Michael Smylie; Nicolas Meyer; Laurent Mortier; Michael B Atkins; Georgina V Long; Shailender Bhatia; Celeste Lebbé; Piotr Rutkowski; Kenji Yokota; Naoya Yamazaki; Tae M Kim; Veerle de Pril; Javier Sabater; Anila Qureshi; James Larkin; Paolo A Ascierto Journal: N Engl J Med Date: 2017-09-10 Impact factor: 91.245
Authors: Paul W Sperduto; T Jonathan Yang; Kathryn Beal; Hubert Pan; Paul D Brown; Ananta Bangdiwala; Ryan Shanley; Norman Yeh; Laurie E Gaspar; Steve Braunstein; Penny Sneed; John Boyle; John P Kirkpatrick; Kimberley S Mak; Helen A Shih; Alex Engelman; David Roberge; Nils D Arvold; Brian Alexander; Mark M Awad; Joseph Contessa; Veronica Chiang; John Hardie; Daniel Ma; Emil Lou; William Sperduto; Minesh P Mehta Journal: JAMA Oncol Date: 2017-06-01 Impact factor: 31.777
Authors: Arsela Prelaj; Roberto Ferrara; Sara Elena Rebuzzi; Claudia Proto; Diego Signorelli; Giulia Galli; Alessandro De Toma; Giovanni Randon; Filippo Pagani; Giuseppe Viscardi; Marta Brambilla; Benedetta Trevisan; Monica Ganzinelli; Antonia Martinetti; Rosaria Gallucci; Rosa Maria Di Mauro; Giuliano Molino; Nicoletta Zilembo; Valter Torri; Filippo Maria de Braud; Marina Chiara Garassino; Giuseppe Lo Russo Journal: Cancers (Basel) Date: 2019-12-05 Impact factor: 6.639
Authors: Jessica M Finlay; Lindsay C Kobayashi; Abram L Wagner; Julia M Porth; Zhenke Wu; Matthew L Boulton Journal: J Community Health Date: 2022-01-25
Authors: James C Lee; Michael D Green; Laura A Huppert; Christine Chow; Robert H Pierce; Adil I Daud Journal: Clin Cancer Res Date: 2021-07-20 Impact factor: 12.531